Skip to main content
. 2020 Mar 20;12:100216. doi: 10.1016/j.ynstr.2020.100216

Fig. 4.

Fig. 4

CCFM1025 treatment regulates the CREB-BDNF/c-Fos pathway. (A) p-CERB/CREB expression in prefrontal cortex (PFC) (n = 6). Representative western blots (three out of six samples) and quantification of band intensities (relative to the expression of GAPDH); (B) c-Fos levels in PFC (n = 3). Representative sections of immuno-fluorescence staining are in Supplemental Fig. S3 The transcript levels of c-fos in PFC (n = 6). (D) Representative immunohistochemical staining of proBDNF in the dorsal hippocampus. DG and CA3 regions are displayed below (E). The histogram indicates the proBDNF levels qualified by staining intensity (n = 3) (F) Mature BDNF (mBDNF) levels in the hippocampus (n = 5–6). Data are means with SEM; Unpaired Student's t-test #P < 0.05, ###P < 0.001, ####P < 0.0001 vs Non-stress Control; One-way ANOVA (or Kruskal-Wallis test) for CUMS, Fluoxetine- and CCFM1025-treated groups, *P < 0.05, **P < 0.01 vs CUMS vehicle treated.